NCT03156738View on ClinicalTrials.gov

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

December 29, 2017

Study Completion Date

December 29, 2017

Conditions
Healthy
Interventions
DRUG

MT-2990

Subjects will receive a single IV dose of MT-2990

DRUG

Placebo

Subjects will receive a single IV dose of placebo

Trial Locations (1)

9728

Pharmaceutical Research Associates (PRA) Health Sciences, NZ Groningen

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY